Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rhea-AI Summary
Vivani Medical (Nasdaq: VANI) reported Q4 and full-year 2025 results and a business update highlighting clinical and preclinical progress for a semaglutide implant (NPM-139) and financing that extends runway into mid-2027.
The company reported sustained preclinical semaglutide exposure with >20% sham-adjusted weight loss for one year, plans to start a Phase 1 study mid-2026 with data possible by end-2026, and raised $41.5M in recent financings.
Positive
- Preclinical efficacy: semaglutide implant showed >20% sham-adjusted weight loss sustained for one year
- Planned Phase 1: NPM-139 Phase 1 initiation targeted mid-2026 with potential data by end of 2026
- Financing raised: $41.5M gross proceeds from 2025–2026 financings
- Cash runway: $16.2M cash and equivalents expected to fund operations into mid-2027
Negative
- Net loss increased: full-year net loss rose to $26.6M from $23.5M, a >10% increase year-over-year
- Cash decline: cash and equivalents decreased to $16.2M from $18.4M year-over-year
News Market Reaction – VANI
In the Mar 27 session, VANI declined 5.56%, reflecting a notable negative market reaction. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 13 | Q3 2025 earnings | Positive | -11.4% | Q3 results, LIBERATE-1 completion, NPM-139 data, additional financings. |
| Aug 13 | Q2 2025 earnings | Positive | +0.8% | Q2 results, $10M equity financing, positive NPM-139 and LIBERATE-1 data. |
| May 13 | Q1 2025 earnings | Positive | -3.8% | Q1 results, multiple equity raises, LIBERATE-1 progress and NPM-139 data. |
| Mar 31 | FY 2024 earnings | Positive | -5.4% | Q4/FY 2024 results, LIBERATE-1 enrollment, NPM-139 preclinical data, financing. |
| Nov 13 | Q3 2024 earnings | Positive | +11.2% | Q3 2024 results, $5M financing, LIBERATE-1 clearance and positive preclinical data. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings and business updates have more often been followed by downside moves, with an average -1.73% next-day reaction and 3 of 5 past earnings showing negative price responses despite generally positive operational updates.
Over the past five earnings-related updates (from Nov 2024 through Nov 2025), Vivani repeatedly highlighted progress in GLP-1 implant programs (LIBERATE-1 and NPM-139), extended its cash runway via multiple equity financings, and advanced plans to spin off Cortigent. Price reactions have been mixed, often negative despite constructive news. Today’s full-year 2025 results and GLP-1/NPM-139 updates continue this pattern of pairing R&D milestones with financing steps and runway extensions into 2026–2027.
Key Terms
semaglutide medical
phase 1 clinical study medical
glp-1 medical
investigational new drug application regulatory
form s-1 regulatory
form 10 regulatory
registered direct offerings financial
net loss financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under development for chronic weight management toward a Phase 1 clinical study with results anticipated by the end of 2026.
Single preclinical administration of semaglutide implant configuration demonstrates continued semaglutide exposure and >
Solid cash position from multiple recent financings will support operations into mid-2027 and enable the projected completion of key milestones including the Phase 1 study of NPM-139.
ALAMEDA, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal™ technology, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.
“2025 was a pivotal year for Vivani. We successfully completed our first-in-human study, LIBERATE-1; we demonstrated feasibility of our technology with semaglutide, the active ingredient in Wegovy® and Ozempic®; and we made progress against strategic decisions that favorably position the Company in the GLP-1 marketplace,” said Vivani Chief Executive Officer Adam Mendelsohn, Ph.D. “The decision to focus on semaglutide was made based on the combination of promising initial preclinical semaglutide implant feasibility data and encouraging results from LIBERATE-1, the first-in-human application of our proprietary NanoPortal implant technology with exenatide. Our encouragement was reinforced after having recently demonstrated sustained preclinical semaglutide exposures and >
Dr. Mendelsohn continued: “In addition, we have made significant progress in advancing our manufacturing capabilities through thoughtful capital equipment purchases and facilities upgrades as part of our efforts to begin preparing for commercial-scale manufacturing. Having also achieved significant clinical operations progress, we project the initiation of our Phase 1 feasibility for NPM-139 (semaglutide implant) for chronic weight management in mid-2026 with data potentially available by the end of this year. This initial Phase 1 study will be conducted in Australia, allowing us to leverage our recent success with LIBERATE-1 and take advantage of the attractive tax incentives provided by the Australian government.”
Recent Business Highlights
On August 5, 2025, Vivani announced plans to support the rapid advancement of NPM-139, a novel semaglutide implant, based on promising results from the LIBERATE-1 clinical study and additional positive data from a preclinical study with a semaglutide implant. LIBERATE-1, the first-in-human application of Vivani’s proprietary NanoPortal implant technology, demonstrated a positive safety and tolerability profile and encouraging performance data. Vivani also announced new NPM-139 (semaglutide implant) preclinical feasibility data that demonstrated approximately
In September 2025, Vivani announced plans to initiate a Phase 1 clinical study for the NPM-139 semaglutide implant program, pending regulatory clearance, along with high-level details of the anticipated study design. The Company also announced parallel preparations to initiate a Phase 2 clinical study of NPM-139 pending enabling results from the Phase 1 study and regulatory feedback. The Company anticipates initiating the Phase 1 study in mid-2026.
The Company plans to continue exploring opportunities for Vivani’s stockholders to potentially realize value in its neuromodulation assets. Cortigent Inc. (“Cortigent”), a wholly owned subsidiary of the Company, filed amendments to its registration statement on Form S-1 with the most recent amendments occurring on March 3 and March 17, 2026.
Including multiple share purchase agreements and registered direct offerings it entered into in 2025 and in 2026 year-to-date, the Company raised
Upcoming Anticipated Milestones
- Phase 1 study results for low-dose NPM-139, Vivani’s miniature, ultra long-acting semaglutide implant under development for chronic weight management, by the end of 2026.
- Investigational New Drug Application for NPM-139 to support the proposed Phase 2 dose-ranging study of this semaglutide implant.
- Transition of Cortigent into an independent, publicly traded company. Currently exploring both a spin-off to be registered on a Form 10 and an IPO to be registered on a Form S-1 registration statement.
Fourth Quarter 2025 Financial Results
Note: Vivani (or the “Company”) refers to the consolidated company including the Biopharm Division and Cortigent. The Biopharm Division refers to the drug implant business, the main focus of the consolidated company.
Cash Balance: As of December 31, 2025, Vivani had cash and cash equivalents totaling
Research and development expenses: Research and development expenses during the fourth quarter of 2025 were
General and administrative expenses: General and administrative expenses during the fourth quarter of 2025 were
Other income (expense): Other income (expense), net during the fourth quarter of 2025 was
Net Loss: The net loss during the fourth quarter of 2025 was
Full Year 2025 Financial Results
Research and development expense. Research and development expense during the year ended December 31, 2025 was
General and administrative expense. General and administrative expense during the year ended December 31, 2025 was
Other income, net. Other income, net during the year ended December 31, 2025 was
Net loss. The net loss during the year ended December 31, 2025 was
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
About Cortigent, Inc.
Cortigent, Inc., a wholly owned subsidiary of Vivani, is developing brain implant devices to help patients recover critical body functions. Our patent-protected precision neurostimulation technology platform leverages neuroscience and proprietary microelectronics to create advanced medical devices. Our predecessor, Second Sight Medical Products, previously marketed Argus® II, the first and only medical device to obtain FDA approval to treat a rare form of blindness. This innovative device has helped hundreds of profoundly blind patients to achieve meaningful visual perception. Cortigent’s next generation investigational system, the Orion® cortical stimulation system, has been designed to treat blindness caused by common conditions including glaucoma and diabetic retinopathy. Orion has an FDA Breakthrough Device designation, completed a 6-year Early Feasibility Study in 2025 with promising safety and efficacy results and is covered by an extensive intellectual property estate. Cortigent is also applying its core technology to improving recovery of arm and hand motion in patients with paralysis due to stroke. For more information and patient videos, please visit: www.cortigent.com.
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development thereof, Vivani’s plans with respect to Cortigent and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks that the spin-off will not be completed in a timely manner or at all; risks of failure to satisfy any conditions to the spin-off; risks of failure of the spin-off to qualify for nonrecognition of gain or loss for U.S. federal income tax purposes; uncertainty of whether the anticipated benefits of the spin-off can be achieved; risks of unexpected costs or delays; and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to market conditions and the ability of Cortigent to complete its spin-off, Cortigent’s history of losses and its ability to access additional capital or otherwise fund its business and advance its product candidates and preclinical programs. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. There may be additional risks that the Company or Cortigent consider immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 26, 2026, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law
Company Contacts:
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462
| VIVANI MEDICAL, INC. AND SUBSIDIARIES Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 16,232 | $ | 18,352 | ||||
| R&D tax credit incentive receivable | 654 | 253 | ||||||
| Prepaid expenses and other current assets | 1,012 | 1,837 | ||||||
| Total current assets | 17,898 | 20,442 | ||||||
| Property and equipment, net | 2,879 | 1,693 | ||||||
| Operating lease right-of-use assets, net | 17,230 | 17,957 | ||||||
| Restricted cash | 1,338 | 1,338 | ||||||
| Deposits and other assets | 48 | 131 | ||||||
| TOTAL ASSETS | $ | 39,393 | $ | 41,561 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 1,032 | $ | 817 | ||||
| Accrued expenses | 1,736 | 1,803 | ||||||
| Litigation accrual | 1,675 | 1,675 | ||||||
| Accrued compensation expense | 365 | 343 | ||||||
| Lease liability, current portion | 1,794 | 1,348 | ||||||
| Total current liabilities | 6,602 | 5,986 | ||||||
| Lease liability, noncurrent portion | 17,061 | 17,965 | ||||||
| TOTAL LIABILITIES | 23,663 | 23,951 | ||||||
| STOCKHOLDERS' EQUITY: | ||||||||
| Preferred stock, par value | — | — | ||||||
| Common stock, par value | 8 | 6 | ||||||
| Additional paid-in capital | 164,225 | 139,480 | ||||||
| Accumulated other comprehensive income | 30 | 48 | ||||||
| Accumulated deficit | (148,533 | ) | (121,924 | ) | ||||
| TOTAL STOCKHOLDERS' EQUITY | 15,730 | 17,610 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 39,393 | $ | 41,561 | ||||
| VIVANI MEDICAL, INC. AND SUBSIDIARIES Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) | ||||||||
| Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Research and development, net of grants | $ | 18,126 | $ | 15,745 | ||||
| General and administrative, net of grants | 9,430 | 8,932 | ||||||
| Total operating expenses | 27,556 | 24,677 | ||||||
| Loss from operations | (27,556 | ) | (24,677 | ) | ||||
| Other income, net | 947 | 1,191 | ||||||
| Net loss | $ | (26,609 | ) | $ | (23,486 | ) | ||
| Net loss per common share - basic and diluted | $ | (0.43 | ) | $ | (0.43 | ) | ||
| Weighted average shares outstanding - basic and diluted | 62,389 | 54,981 | ||||||
